Literature DB >> 15044600

Aortic adaptation to pregnancy: elevated expression of matrix metalloproteinases-2 and -3 in rat gestation.

B A Kelly1, B C Bond, L Poston.   

Abstract

The maternal aorta undergoes substantial functional and structural adaptation in pregnancy. Both aortic diameter and compliance are increased and studies of animal and human gestation indicate that these changes are initiated in early pregnancy and maintained until delivery. The mechanisms underlying aortic adaptation in normal pregnancy remain largely unknown but matrix metalloproteinase enzymes (MMP) are likely to play a key role. Gene expression of candidate MMP and specific tissue inhibitors of MMP (TIMP) were investigated in non-pregnant, pregnant (days 7, 14, 21) and postpartum (day 7) rat aorta using real-time PCR. Of the gene transcripts studied (MMP-2, -3, -7, -9, -12, -13, MT1MMP, TIMP-1, -2) in rat aorta, only MMP-3 was significantly elevated with a 24-fold increase observed in late gestation compared to virgin control (P = 0.0001). MMP-2 mRNA appeared constitutively expressed and unchanged at time-points studied, but MMP-2 activity as assessed by gelatin zymography suggested further modulation after transcription and/or post-translation in rat aorta with activity increased in early pregnancy (P < 0.01, compared to virgin control). These data suggest that MMP-2 and MMP-3 may contribute to adaptive processes in the maternal rat aorta at different gestations and further support a role for this family of enzymes in physiological vascular remodelling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044600     DOI: 10.1093/humrep/gah045

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  13 in total

Review 1.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

2.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

Review 3.  Central and peripheral neuroimmune responses: hyporesponsiveness during pregnancy.

Authors:  Sarah J Spencer; Abdeslam Mouihate; Michael A Galic; Quentin J Pittman
Journal:  J Physiol       Date:  2007-10-18       Impact factor: 5.182

Review 4.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

5.  Impact of Immune Deficiency on Remodeling of Maternal Resistance Vasculature 4 Weeks Postpartum in Mice.

Authors:  Elizabeth A Bonney; Ann Howard; Kendall Krebs; Kelly Begin; Kelsey Veilleux; Natalia I Gokina
Journal:  Reprod Sci       Date:  2017-01-19       Impact factor: 3.060

Review 6.  Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia.

Authors:  Kirk P Conrad
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

Review 7.  Unveiling the vasodilatory actions and mechanisms of relaxin.

Authors:  Kirk P Conrad
Journal:  Hypertension       Date:  2010-05-24       Impact factor: 10.190

Review 8.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

9.  Effects of global cerebral ischemia in the pregnant rat.

Authors:  Sarah J Spencer; Michael A Galic; Mio Tsutsui; Quentin J Pittman; Abdeslam Mouihate
Journal:  Stroke       Date:  2008-01-31       Impact factor: 7.914

Review 10.  Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Stephanie J Sheppard; Raouf A Khalil
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.